If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Share News (CSRT)

  • There is currently no data for CSRT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Consort Medical First Half Profit Falls Due To Cramlington Incident

Tue, 03rd Dec 2019 09:14

(Alliance News) - Consort Medical PLC on Tuesday said its interim profit was considerably smaller following an incident at its Aesica Cramlington manufacturing facility.

Consort's pretax profit for the six months ended October 31 was GBP1.2 million, far less than the GBP9.6 million profit posted the year before as revenue fell 4.3% to GBP146.0 million from GBP152.5 million.

This was primarily caused by the Cramlington incident, in which a small area of the Northumberland-based operating plant was damaged in what was described by Consort at the time as "the rapid thermal degradation of a chemical resulting in the expulsion of material and contamination of the facility".

This hurt the performance of its active pharmaceutical ingredients and finished dose manufacturing unit, Aesica, where revenue fell 11% to GBP81.1 million from GBP90.9 million.

Bespak, Consort's drug delivery devices unit, was unaffected, with revenue up 5.4% at GBP64.9 million versus GBP61.6 million the year prior.

On November 18, following the end of its first half, contract development and manufacturing pharmaceutical company Consort agreed to a GBP505 million bid from Swedish peer Recipharm AB. Recipharm will pay 1,010 pence in cash for each Consort share. The proposed deal implies an enterprise value of GBP627 million for Consort.

Given that Recipharm may reduce its acquisition consideration if any dividend or other distribution is made by the Hemel Hempstead-based company, Consort has opted not to declare an interim dividend.

Consort Chief Executive Jonathan Glenn said: "The board's expectations for the full year remain unchanged. We anticipate that the group's performance in the second half of the year will benefit from continued growth in Bespak, recommencing manufacture of the specific product involved in the Cramlington incident and a reduction in the backlog at Aesica.

"The group is subject to a recommended offer from Recipharm Holdings Ltd. The board remains confident of Consort's future prospects."

Shares in Consort were down 0.5% at 1,040.00 pence in London on Tuesday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
9 Feb 2015 06:15

UK Dividends Calendar - Week Ahead

Read more
6 Feb 2015 16:01

UK Dividends Calendar - Week Ahead

Read more
4 Feb 2015 14:35

Sector movers: GSK leads defensive pharma stocks higher

A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high. Sales, profits and earnings slumped during the fourth quarter of

Read more
4 Feb 2015 08:23

Consort Medical Signs Multi-Year Supply Agreement

Read more
29 Jan 2015 10:53

Consort Medical Invests Further GBP2.2 Million In Atlas Genetics

Read more
15 Jan 2015 06:21

UK Dividends Calendar - Week Ahead

Read more
14 Jan 2015 16:04

UK Dividends Calendar - Week Ahead

Read more
14 Jan 2015 06:15

UK Dividends Calendar - Week Ahead

Read more
13 Jan 2015 16:01

UK Dividends Calendar - Week Ahead

Read more
13 Jan 2015 06:24

UK Dividends Calendar - Week Ahead

Read more
12 Jan 2015 16:24

UK Dividends Calendar - Week Ahead

Read more
12 Jan 2015 06:18

UK Dividends Calendar - Week Ahead

Read more
9 Jan 2015 16:09

UK Dividends Calendar - Week Ahead

Read more
9 Jan 2015 06:20

UK Dividends Calendar - Week Ahead

Read more
4 Dec 2014 08:46

Thursday broker round-up

Aberdeen: Charles Stanley downgrades to 'hold'. Afren: Canaccord reduces target price from 115p to 65p, while staying with its 'speculative buy' recommendation. Amino Technologies: Northland moves target price from 120p to 130p and retains a 'buy' recommendation. Belgravium Technologies: WH Irelan

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.